Sapreme Technologies BV

📍 Utrecht, Netherlands🗓 Founded 2016👥 12 employees
Biotechnology Research🌐 sapreme-technologies.com
Website LinkedIn
Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication. Our solution to endosomal entrapment has the potential to re-open myriad drug development pathways for macromolecule therapeutics lacking efficacy and to explore new targets considered “undruggable” by permeabilizing endo-lysosomal membranes, allowing trapped macromolecules to be released, increasing target engagement without negatively impacting the plasma membrane integrity.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Sapreme Technologies BV founded?
Sapreme Technologies BV was founded in 2016.
What industry is Sapreme Technologies BV in?
Sapreme Technologies BV operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Sapreme Technologies BV based?
Sapreme Technologies BV is headquartered in Utrecht, Netherlands.